Kersti Oselin

1a L. Puusepa Street
Tartu, 50406, Estonia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.

Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.

Journal: Molecular oncology

Published: March 23, 2026

LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme.

LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme.

Journal: BMJ open

Published: November 17, 2025

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 12, 2025

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

Journal: Frontiers in oncology

Published: August 07, 2025

Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.

Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.

Journal: NPJ genomic medicine

Published: July 21, 2025

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 18, 2025

Lung Cancer in Estonia.

Lung Cancer in Estonia.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 20, 2024

An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations.

An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 25, 2024

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability.

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability.

Journal: BMC proceedings

Published: January 17, 2024

Pharmacokinetics of oral spironolactone in infants up to 2 years of age.

Pharmacokinetics of oral spironolactone in infants up to 2 years of age.

Journal: European journal of clinical pharmacology

Published: June 22, 2023

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.

EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.

Journal: NPJ precision oncology

Published: May 22, 2023

Genomic alterations as independent prognostic factors to predict the type of lung cancer recurrence.

Genomic alterations as independent prognostic factors to predict the type of lung cancer recurrence.

Journal: Gene

Published: May 10, 2023

Showing 1-12 of 24

Last Updated: 09/26/2026